The aim of our research and development efforts in endocrinology is to offer patients with growth disorders and metabolic diseases new therapeutic options or improved versions of established products based on our own development work or cooperation with partners. The most recent examples include Egrifta™ (tesamorelin for injection) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, as well as the development of a liquid formulation of Saizen® for injection.
back
